Compare Cipla with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ASTRAZENECA PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ASTRAZENECA PHARMA CIPLA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 36.7 141.2 26.0% View Chart
P/BV x 4.3 39.6 10.7% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 CIPLA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-20
ASTRAZENECA PHARMA
Mar-18
CIPLA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs5861,278 45.8%   
Low Rs357883 40.4%   
Sales per share (Unadj.) Rs207.0228.4 90.6%  
Earnings per share (Unadj.) Rs18.610.4 179.4%  
Cash flow per share (Unadj.) Rs33.216.3 204.0%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs195.598.8 197.9%  
Shares outstanding (eoy) m806.3525.00 3,225.4%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.34.7 48.1%   
Avg P/E ratio x25.3104.2 24.3%  
P/CF ratio (eoy) x14.266.4 21.4%  
Price / Book Value ratio x2.410.9 22.0%  
Dividend payout %21.50-   
Avg Mkt Cap Rs m379,91227,008 1,406.7%   
No. of employees `00025.81.4 1,906.0%   
Total wages/salary Rs m30,2701,535 1,971.6%   
Avg. sales/employee Rs Th6,459.64,210.9 153.4%   
Avg. wages/employee Rs Th1,171.21,132.2 103.4%   
Avg. net profit/employee Rs Th580.2191.1 303.6%   
INCOME DATA
Net Sales Rs m166,9495,710 2,923.8%  
Other income Rs m3,442123 2,809.8%   
Total revenues Rs m170,3915,833 2,921.4%   
Gross profit Rs m32,060463 6,925.9%  
Depreciation Rs m11,747147 7,969.1%   
Interest Rs m1,9740-   
Profit before tax Rs m21,782438 4,973.0%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,312179 3,528.2%   
Profit after tax Rs m14,995259 5,787.4%  
Gross profit margin %19.28.1 236.9%  
Effective tax rate %29.040.8 70.9%   
Net profit margin %9.04.5 197.9%  
BALANCE SHEET DATA
Current assets Rs m117,0383,209 3,647.0%   
Current liabilities Rs m43,9312,070 2,122.8%   
Net working cap to sales %43.820.0 219.4%  
Current ratio x2.71.6 171.8%  
Inventory Days Days9672 132.3%  
Debtors Days Days8535 243.6%  
Net fixed assets Rs m107,424790 13,592.8%   
Share capital Rs m1,61350 3,225.0%   
"Free" reserves Rs m156,0182,419 6,448.9%   
Net worth Rs m157,6302,469 6,383.6%   
Long term debt Rs m23,6930-   
Total assets Rs m236,6264,605 5,138.0%  
Interest coverage x12.0NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.71.2 56.9%   
Return on assets %7.25.6 127.5%  
Return on equity %9.510.5 90.7%  
Return on capital %12.817.7 72.4%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,036300 18,706.7%   
Fx outflow Rs m6,7642,015 335.7%   
Net fx Rs m49,272-1,715 -2,872.4%   
CASH FLOW
From Operations Rs m30,68588 34,908.4%  
From Investments Rs m1,040-94 -1,111.5%  
From Financial Activity Rs m-29,488NA-  
Net Cashflow Rs m2,340-6 -41,056.1%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 0.3 4,066.7%  
FIIs % 23.7 15.7 151.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 9.1 287.9%  
Shareholders   161,166 12,856 1,253.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SHASUN PHARMA  WYETH  TORRENT PHARMA  SUVEN LIFE SCIENCES  DR. REDDYS LAB  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends at Record High; Tata Motors and Adani Ports Among Top Nifty Gainers(Closing)

Indian share markets extended gains to the second day today and ended at record-high levels with Nifty ending above 14,600-mark.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 20, 2021 03:36 PM

TRACK CIPLA

CIPLA - AUROBINDO PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS